STOCK TITAN

Molecular Partners AG - MOLN STOCK NEWS

Welcome to our dedicated news page for Molecular Partners (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on Molecular Partners.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Molecular Partners's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Molecular Partners's position in the market.

Rhea-AI Summary
Molecular Partners AG will present additional positive data from its Phase 1 study of MP0317 in patients with advanced solid tumors. The study shows tumor-localized CD40 activation and a favorable safety profile. Patient recruitment for the dose-escalation portion is complete, with final results expected in H1 2024. The data support further clinical evaluation of MP0317, including combination studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
-
Rhea-AI Summary
Molecular Partners AG will present preliminary data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data indicate an acceptable safety profile with no dose-limiting toxicity or Grade ≥3 adverse reactions. One patient in the third treatment cohort achieved a response. The study is enrolling its fifth cohort, and additional data will be presented at the ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
conferences clinical trial
-
Rhea-AI Summary
Molecular Partners AG, a clinical-stage biotech company, will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3, 2023. The event will feature Patrick Amstutz, CEO, and Dr. Philippe Legenne, acting CMO. A live webcast will be available on the company's website, with a replay archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
conferences
Rhea-AI Summary
Molecular Partners announces corporate highlights and unaudited financial results for Q3 2023. Phase 1 dose escalation recruitment completed for MP0317 in advanced solid tumors. MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned. Radio-DARPin Therapy platform continues to progress. Company funded well into 2026 with CHF 207 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
-
Rhea-AI Summary
Molecular Partners announces new data from its Radio-DARPin Therapy (RDT) platform, showing increased tumor uptake and reduced accumulation in kidneys. The engineering solutions applied to optimize the RDT platform are transferrable to different tumor-associated antigens, potentially expanding the target space for radioligand therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary
Molecular Partners AG announces positive progress in clinical trials and financial results for H1 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
conferences
Molecular Partners AG

Nasdaq:MOLN

MOLN Rankings

MOLN Stock Data

129.83M
16.99M
2.63%
0.15%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Switzerland
Schlieren